RNPEP antibodies are immunoreagents designed to detect arginyl aminopeptidase (aminopeptidase B), encoded by the RNPEP gene. These antibodies facilitate the study of RNPEP's enzymatic activity, localization, and expression across tissues. Key characteristics include:
Host/Isotype: Primarily rabbit-derived IgG polyclonal antibodies .
Immunogen: Typically recombinant proteins or fusion peptides (e.g., Proteintech’s Ag6526 fusion protein) .
Reactivity: Confirmed in human, mouse, and rat samples, with cross-reactivity validation in cell lines (e.g., HeLa, A549) and tissues (liver, lung cancer) .
RNPEP antibodies are validated for multiple techniques:
Cancer Metastasis: RNPEP in tumor exosomes promotes lung metastasis in liver cancer by activating cancer-associated fibroblasts .
Neurological Disorders: Reduced RNPEP levels in Mecp2-deficient mice (Rett syndrome model) suggest its role in cortical protein regulation .
Antigen Retrieval: For IHC, TE buffer (pH 9.0) or citrate buffer (pH 6.0) enhances detection in formalin-fixed tissues .
Validation: Specificity confirmed via protein arrays (Novus Biologicals) and knockdown/knockout models .
Specificity: Verified using siRNA knockdown and immunoblotting .
Cross-Reactivity: No significant binding to 383 non-target proteins in array testing .
Batch Consistency: Antigen-affinity purification ensures high lot-to-lot reproducibility .